Adicet Bio, Inc

Adicet Bio, Inc company information, Employees & Contact Information

Explore related pages

Related company profiles:

At Adicet (Nasdaq: ACET), we are defined by our mission to deliver best-in-class gamma-delta T cell therapies for patients fighting autoimmune diseases and cancer. Every one of our team members, whether in the lab, manufacturing, or general business role, comes to work every day with the patient in mind. As pioneers in the cell therapy space, we are honored and humbled by the opportunity to put our talents to bear in developing transformative therapies to defeat autoimmune diseases and cancer. We believe that the best way to do this is through discovering and developing allogeneic gamma-delta T cell therapies, a novel type of cell therapy. Adicet has chosen the gamma-delta T cell because it: • Preferentially traffics to tissues and provides B cell depletion, potentially leading to an immune reset for patients with autoimmune diseases. • Has multiple ways to target and kill cancer cells including solid tumors. We also chose to use cells from donors (allogeneic) to enable our potential therapies to be readily available when needed (taken “off-the-shelf” or available to the patient on demand). We’re not just blazing new trails in cell therapy, we’re having fun along the way. With regular team gatherings, many shared meals, larger company events, and a consistent commitment to our values, we have a strong culture! We are proud to attract and retain some of the greatest talent in the biopharma and cell therapy space, and we’re consistently giving back to our employees. The Adicet benefits package includes generous financial compensation, comprehensive health plans, generous paid time-off, educational reimbursement, and access to many amenities in our state-of-the-art facility. To learn more or inquire about joining our team in Boston, MA or Redwood City, CA, please visit http://www.adicetbio.com

Company Details

Employees
144
Address
1000 Bridge Pkwy, Redwood City,california 94065,united States
Phone
(310) 990-3832
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Redwood City, California
Looking for a particular Adicet Bio, Inc employee's phone or email?

Adicet Bio, Inc Questions

News

Adicet Bio (NASDAQ: ACET) to join Nov 11, 3:00 p.m. ET fireside chat; webcast - Stock Titan

Adicet Bio (NASDAQ: ACET) to join Nov 11, 3:00 p.m. ET fireside chat; webcast Stock Titan

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Business Wire

Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases - Yahoo Finance

Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases Yahoo Finance

Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) - Business Wire

Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) Business Wire

Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting - FinancialContent

Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting FinancialContent

84,000 Shares at $0.72: Adicet Bio's Latest Inducement Grants Under Nasdaq Rule 5635(c)(4) - Stock Titan

84,000 Shares at $0.72: Adicet Bio's Latest Inducement Grants Under Nasdaq Rule 5635(c)(4) Stock Titan

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones - Yahoo Finance

Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones Yahoo Finance

Clinical & Translational Immunology | ASI Journal - Wiley Online Library

Clinical & Translational Immunology | ASI Journal Wiley Online Library

Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates - Business Wire

Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates Business Wire

Biomarker Data from Oncology Trial for Adicet Bio’s Gamma Delta T-cell Therapy ADI-001 Indicates Potential for Use in Autoimmune Disease - CGTLive®

Biomarker Data from Oncology Trial for Adicet Bio’s Gamma Delta T-cell Therapy ADI-001 Indicates Potential for Use in Autoimmune Disease CGTLive®

FDA Grants Fast Track Designation to Adicet Bio’s CAR T-cell Therapy for Systemic Lupus Erythematosus - Pharmaceutical Executive

FDA Grants Fast Track Designation to Adicet Bio’s CAR T-cell Therapy for Systemic Lupus Erythematosus Pharmaceutical Executive

Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer - citybiz

Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer citybiz

FDA Fast Tracks CAR-T Therapy for Lupus - HCPLive

FDA Fast Tracks CAR-T Therapy for Lupus HCPLive

FDA fast tracks ADI-270 for clear cell renal cell carcinoma - Urology Times

FDA fast tracks ADI-270 for clear cell renal cell carcinoma Urology Times

Adicet Bio, Inc. Announces Pricing of Public Offering of Common Stock - GlobeNewswire

Adicet Bio, Inc. Announces Pricing of Public Offering of Common Stock GlobeNewswire

First patient dosed: Adicet Bio's ADI-001 begins Phase 1 trial in treatment‑refractory RA; data 2H/2026 - Stock Titan

First patient dosed: Adicet Bio's ADI-001 begins Phase 1 trial in treatment‑refractory RA; data 2H/2026 Stock Titan

70.0M shares: Adicet Bio Prices $80M Registered Direct Offering - Stock Titan

70.0M shares: Adicet Bio Prices $80M Registered Direct Offering Stock Titan

Adicet Bio Clinical Trial Now Targets 6 Autoimmune Diseases as Company Streamlines for Growth - Stock Titan

Adicet Bio Clinical Trial Now Targets 6 Autoimmune Diseases as Company Streamlines for Growth Stock Titan

Adicet Bio, Inc. Announces Pricing of Public Offering - The AI Journal

Adicet Bio, Inc. Announces Pricing of Public Offering The AI Journal

Adicet Announces Completion of Merger with resTORbio - GlobeNewswire

Adicet Announces Completion of Merger with resTORbio GlobeNewswire

Adicet Bio Appoints Francesco Galimi, M.D., Ph.D., SVP and Chief Medical Officer - PR Newswire

Adicet Bio Appoints Francesco Galimi, M.D., Ph.D., SVP and Chief Medical Officer PR Newswire

Adicet Bio Announces the Transition of Founder, President and Chief Executive Officer Dr. Aya Jakobovits - PR Newswire

Adicet Bio Announces the Transition of Founder, President and Chief Executive Officer Dr. Aya Jakobovits PR Newswire

User - FinancialContent

User FinancialContent

User - FinancialContent

User FinancialContent

resTORbio and Adicet Bio Announce Merger Agreement to - GlobeNewswire

resTORbio and Adicet Bio Announce Merger Agreement to GlobeNewswire

Adicet Announces Appointment of Katie Peng to the Board of Directors | User | thepilotnews.com - FinancialContent

Adicet Announces Appointment of Katie Peng to the Board of Directors | User | thepilotnews.com FinancialContent

Adicet Bio Appoints Jesse McGreivy, M.D., Chief Medical Officer - PR Newswire

Adicet Bio Appoints Jesse McGreivy, M.D., Chief Medical Officer PR Newswire

Top Adicet Bio, Inc Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant